2025-04-30T10:00:00Z

---

A recent national survey conducted by the Alzheimer's Association has unveiled a significant shift in attitudes among older Americans regarding Alzheimer's disease. The survey, which involved 1,700 participants aged 45 and older, highlights a growing willingness among individuals to seek testing for the disease, particularly through blood tests. This change is underscored by the alarming reality that over 7 million people in the United States are currently living with Alzheimer's, a condition that poses a serious impact on cognitive health.

According to the findings of the survey, nearly 80% of respondentsequivalent to 79%expressed a desire to know if they had Alzheimer's before symptoms began to disrupt their daily lives. This proactive approach marks a notable departure from previous attitudes, where many would hesitate to seek such diagnoses due to fear or uncertainty. Furthermore, 80% stated they would proactively request testing from their physicians rather than wait for such an opportunity to be presented.

One of the most striking revelations from the survey is the overwhelming demand for accessible testing methods. A remarkable 91% of participants indicated they would prefer a blood biomarker test or some form of straightforward testing if it were available. Interestingly, many respondents were unaware that several blood tests currently on the market can already indicate the presence of amyloid plaques in the brain, a key indicator of Alzheimer's disease.

In terms of treatment readiness, 92% of participants confirmed that they would be inclined to take a drug aimed at slowing the progression of Alzheimer's if diagnosed, especially given the recent approval of drugs like lecanemab and donanemab that target individuals in the early stages of the disease. Additionally, 58% of respondents indicated they would consider taking an Alzheimer's medication despite a moderate to high risk of side effects, demonstrating a heightened willingness to combat the disease.

The survey also shed light on the willingness of individuals to participate in clinical trials, with 83% expressing openness to engaging in experimental treatments designed to either slow or potentially cure Alzheimer's. Respondents maintain a hopeful outlook, with 81% anticipating the arrival of effective treatments within the next decade. However, amidst this optimism, 44% expressed concern about the possibility that insurance may not cover treatment and care if they were to test positive for the disease.

Elizabeth Edgerly, a clinical psychologist and director of community programs for the Alzheimer's Association, interprets these results as indicative of a broader cultural shift. She notes that individuals are becoming less fearful and more proactive about understanding their health. In previous years, many of her clients would voice sentiments of reluctance, questioning the value of knowing their status.

There are several reasons for this evolving mindset. One significant factor is the advancements in testing methodologies, which have made it easier to confirm the presence of amyloid plaques. Just a few years ago, diagnosis typically required invasive procedures like PET scans or spinal taps. Today, simple blood tests can yield crucial information, encouraging individuals to seek clarity on their cognitive health.

The introduction of treatment options for early-stage Alzheimer's also plays a pivotal role. Edgerly emphasizes the importance of obtaining a diagnosis while individuals are still capable of making informed decisions about their future. When symptoms remain mild, patients can articulate their desires regarding treatment options and plan accordingly.

Dr. Nathaniel Chin, a geriatrician at the University of Wisconsin, who did not participate in the survey, agrees that the emergence of drug therapies has fostered a sense of optimism among those at risk for Alzheimer's. He notes that even if current medications do not halt the disease's progression entirely, their existence signals significant progress in the field. Patients are eager to learn about their potential eligibility for these therapies now and in the future.

Despite the changing public sentiment, some medical professionals remain cautious about the utility of early testing. Dr. Chin notes that a portion of the medical community views existing treatments as only marginally effective. He remarks, Some patients are ahead of their doctors in this regard, indicating a growing demand among patients for Alzheimer's information that sometimes surpasses their doctors' willingness to engage.

In his own practice, Dr. Chin offers blood tests to patients exhibiting cognitive issues and anticipates that such testing will become increasingly common. However, he acknowledges that this trend may introduce new challenges, particularly regarding the counseling of individuals who receive a positive diagnosis. A positive result could have implications for employment and health insurance, raising concerns about the lack of protective measures for those who learn about their cognitive health status.

Dr. Chin reminds us that while there are certain protections in place for individuals who learn their genetic information, there are currently no safeguards for those who discover that they are cognitively impaired or healthy. As the demand for testing grows, it will be essential for organizations such as the Alzheimer's Association to advocate for necessary protections to ensure that individuals are not adversely affected by their health information.